BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Eckel F, von Delius S, Mayr M, Dobritz M, Fend F, Hosius C, Schleyer E, Schulte-Frohlinde E, Schmid RM, Lersch C. Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. Oncology. 2005;69:363-371. [PMID: 16319507 DOI: 10.1159/000089990] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Siegel A. Moving targets in hepatocellular carcinoma: hepatic progenitor cells as novel targets for tyrosine kinase inhibitors. Gastroenterology 2008;135:733-5. [PMID: 18692053 DOI: 10.1053/j.gastro.2008.07.036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
2 Du ZQ, Dong J, Li MX, Zhang JF, Bi JB, Ren YF, Zhang LN, Wu RQ, Monga SPS, Lv Y, Zhang XF, Wang HC. Overexpression of Platelet-Derived Growth Factor Receptor Α D842V Mutants Prevents Liver Regeneration and Chemically Induced Hepatocarcinogenesis via Inhibition of MET and EGFR. J Cancer 2020;11:4614-24. [PMID: 32489479 DOI: 10.7150/jca.44492] [Reference Citation Analysis]
3 Wörns MA, Galle PR. Novel inhibitors in development for hepatocellular carcinoma. Expert Opin Investig Drugs 2010;19:615-29. [PMID: 20374038 DOI: 10.1517/13543781003767418] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
4 Raica M, Cimpean AM. Platelet-Derived Growth Factor (PDGF)/PDGF Receptors (PDGFR) Axis as Target for Antitumor and Antiangiogenic Therapy. Pharmaceuticals (Basel) 2010;3:572-99. [PMID: 27713269 DOI: 10.3390/ph3030572] [Cited by in Crossref: 103] [Cited by in F6Publishing: 78] [Article Influence: 9.4] [Reference Citation Analysis]
5 Midorikawa Y, Sugiyama Y, Aburatani H. Screening of liver-targeted drugs. Expert Opinion on Drug Discovery 2008;3:643-54. [DOI: 10.1517/17460441.3.6.643] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
6 Shen YC, Hsu C, Cheng AL. Molecular targeted therapy for advanced hepatocellular carcinoma. Targ Oncol 2007;2:199-210. [DOI: 10.1007/s11523-007-0058-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
7 Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Thng CH, Chow P, Ong HS, Chung A, Soo KC. Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med 2009;13:2673-83. [PMID: 19220580 DOI: 10.1111/j.1582-4934.2009.00692.x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 84] [Article Influence: 7.7] [Reference Citation Analysis]
8 Midorikawa Y, Sugiyama Y, Aburatani H. Molecular targets for liver cancer therapy: From screening of target genes to clinical trials. Hepatol Res 2010;40:49-60. [PMID: 19788683 DOI: 10.1111/j.1872-034X.2009.00583.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
9 Campbell JS, Johnson MM, Bauer RL, Hudkins KL, Gilbertson DG, Riehle KJ, Yeh MM, Alpers CE, Fausto N. Targeting stromal cells for the treatment of platelet-derived growth factor C-induced hepatocellular carcinogenesis. Differentiation. 2007;75:843-852. [PMID: 17999742 DOI: 10.1111/j.1432-0436.2007.00235.x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
10 Chan LS, Daruwalla J, Christophi C. Selective targeting of the tumour vasculature. ANZ J Surg 2008;78:955-67. [PMID: 18959693 DOI: 10.1111/j.1445-2197.2008.04712.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
11 Mizuguchi Y, Takizawa T, Yoshida H, Uchida E. Dysregulated miRNA in progression of hepatocellular carcinoma: A systematic review. Hepatol Res. 2016;46:391-406. [PMID: 26490438 DOI: 10.1111/hepr.12606] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 10.8] [Reference Citation Analysis]
12 Oseini AM, Roberts LR. PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma? Expert Opin Ther Targets 2009;13:443-54. [PMID: 19335066 DOI: 10.1517/14728220902719233] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
13 Roberts LR, Gores GJ. Emerging drugs for hepatocellular carcinoma. Expert Opinion on Emerging Drugs 2006;11:469-87. [DOI: 10.1517/14728214.11.3.469] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
14 Becker G, Schmitt-Graeff A, Ertelt V, Blum HE, Allgaier HP. CD117 (c-kit) expression in human hepatocellular carcinoma. Clin Oncol (R Coll Radiol). 2007;19:204-208. [PMID: 17359908 DOI: 10.1016/j.clon.2006.12.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
15 Thomas MB, Chadha R, Glover K, Wang X, Morris J, Brown T, Rashid A, Dancey J, Abbruzzese JL. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer. 2007;110:1059-1067. [PMID: 17623837 DOI: 10.1002/cncr.22886] [Cited by in Crossref: 221] [Cited by in F6Publishing: 197] [Article Influence: 15.8] [Reference Citation Analysis]
16 Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, Wolf  J, Jaehde U. Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors: Focus on Pyrimidines, Pyridines and Pyrroles. Clinical Pharmacokinetics 2011;50:551-603. [DOI: 10.2165/11593320-000000000-00000] [Cited by in Crossref: 132] [Cited by in F6Publishing: 103] [Article Influence: 13.2] [Reference Citation Analysis]
17 Zhu AX. Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful Should We Be? The Oncologist 2006;11:790-800. [DOI: 10.1634/theoncologist.11-7-790] [Cited by in Crossref: 181] [Cited by in F6Publishing: 161] [Article Influence: 12.1] [Reference Citation Analysis]
18 Treiber G, Wex T, Schleyer E, Troeger U, Hosius C, Malfertheiner P. Imatinib for hepatocellular cancer--focus on pharmacokinetic/pharmacodynamic modelling and liver function. Cancer Lett. 2008;260:146-154. [PMID: 18083304 DOI: 10.1016/j.canlet.2007.10.041] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
19 Kara B, Doran F, Kara IO, Akkiz H, Sandikci M. Expression of c-kit protooncogen in hepatitis B virus-induced chronic hepatitis, cirrhosis and hepatocellular carcinoma: has it a diagnostic role?: Expression of c-kit in hepatitis B virus induced hepatocellular carcinoma. International Journal of Clinical Practice 2008;62:1206-11. [DOI: 10.1111/j.1742-1241.2007.01675.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
20 van Erp NP, Gelderblom H, Guchelaar HJ. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009;35:692-706. [PMID: 19733976 DOI: 10.1016/j.ctrv.2009.08.004] [Cited by in Crossref: 272] [Cited by in F6Publishing: 209] [Article Influence: 22.7] [Reference Citation Analysis]
21 Kil KE, Ding YS, Lin KS, Alexoff D, Kim SW, Shea C, Xu Y, Muench L, Fowler JS. Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec). Nucl Med Biol 2007;34:153-63. [PMID: 17307123 DOI: 10.1016/j.nucmedbio.2006.11.004] [Cited by in Crossref: 53] [Cited by in F6Publishing: 40] [Article Influence: 3.8] [Reference Citation Analysis]
22 Kern MA, Breuhahn K, Schuchmann M, Schirmacher P. [Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology]. Pathologe 2007;28:261-8. [PMID: 17605064 DOI: 10.1007/s00292-007-0890-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
23 Pinter M, Trauner M, Peck-Radosavljevic M, Sieghart W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016;1:e000042. [PMID: 27843598 DOI: 10.1136/esmoopen-2016-000042] [Cited by in Crossref: 108] [Cited by in F6Publishing: 72] [Article Influence: 21.6] [Reference Citation Analysis]
24 Wang W, Shui L, Liu Y, Zheng M. C-Kit, a Double-Edged Sword in Liver Regeneration and Diseases. Front Genet 2021;12:598855. [PMID: 33603771 DOI: 10.3389/fgene.2021.598855] [Reference Citation Analysis]
25 Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, Hiddingh L, Roberge S, Koppel C, Lauwers GY, Zhu AX, Jain RK, Duda DG. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology. 2014;59:1435-1447. [PMID: 24242874 DOI: 10.1002/hep.26790] [Cited by in Crossref: 114] [Cited by in F6Publishing: 107] [Article Influence: 16.3] [Reference Citation Analysis]
26 Mínguez B, Tovar V, Chiang D, Villanueva A, Llovet JM. Pathogenesis of hepatocellular carcinoma and molecular therapies. Curr Opin Gastroenterol. 2009;25:186-194. [PMID: 19387255 DOI: 10.1097/mog.0b013e32832962a1] [Cited by in Crossref: 101] [Cited by in F6Publishing: 48] [Article Influence: 8.4] [Reference Citation Analysis]
27 Lee TK, Castilho A, Ma S, Ng IO. Liver cancer stem cells: implications for a new therapeutic target. Liver Int. 2009;29:955-965. [PMID: 19490415 DOI: 10.1111/j.1478-3231.2009.02040.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 45] [Article Influence: 4.6] [Reference Citation Analysis]
28 Alves A, Mamede A, Alves M, Oliveira P, Rocha S, Botelho M, Maia C. Glycolysis Inhibition as a Strategy for Hepatocellular Carcinoma Treatment? CCDT 2018;19:26-40. [DOI: 10.2174/1568009618666180430144441] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
29 Lin AY, Fisher GA, So S, Tang C, Levitt L. Phase II study of imatinib in unresectable hepatocellular carcinoma. Am J Clin Oncol. 2008;31:84-88. [PMID: 18376233 DOI: 10.1097/coc.0b013e3181131db9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
30 Schiavon G, Eechoute K, Mathijssen RHJ, de Bruijn P, van der Bol JM, Verweij J, Sleijfer S, Loos WJ. Biliary Excretion of Imatinib and Its Active Metabolite CGP74588 During Severe Hepatic Dysfunction. The Journal of Clinical Pharmacology 2012;52:1115-20. [DOI: 10.1177/0091270011409235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
31 Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 2009;27:3027-3035. [PMID: 19470923 DOI: 10.1200/jco.2008.20.9908] [Cited by in Crossref: 353] [Cited by in F6Publishing: 168] [Article Influence: 29.4] [Reference Citation Analysis]
32 Murray M, Gillani TB, Ghassabian S, Edwards RJ, Rawling T. Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver. European Journal of Pharmaceutical Sciences 2018;114:55-63. [DOI: 10.1016/j.ejps.2017.12.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
33 Mizuguchi Y, Takizawa T, Uchida E. Host cellular microRNA involvement in the control of hepatitis B virus gene expression and replication. World J Hepatol. 2015;7:696-702. [PMID: 25866606 DOI: 10.4254/wjh.v7.i4.696] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
34 Gramantieri L, Fornari F, Callegari E, Sabbioni S, Lanza G, Croce CM, Bolondi L, Negrini M. MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med 2008;12:2189-204. [PMID: 19120703 DOI: 10.1111/j.1582-4934.2008.00533.x] [Cited by in Crossref: 182] [Cited by in F6Publishing: 175] [Article Influence: 15.2] [Reference Citation Analysis]
35 Kamenz T, Caca K, Blüthner T, Tannapfel A, Mössner J, Wiedmann M. Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric mice. World J Gastroenterol 2006;12:1583-90. [PMID: 16570351 DOI: 10.3748/wjg.v12.i10.1583] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
36 Ramanathan RK, Egorin MJ, Takimoto CH, Remick SC, Doroshow JH, Lorusso PA, Mulkerin DL, Grem JL, Hamilton A, Murgo AJ, Potter DM, Belani CP, Hayes MJ, Peng B, Ivy SP. Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group. JCO 2008;26:563-9. [DOI: 10.1200/jco.2007.11.0304] [Cited by in Crossref: 72] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
37 Villanueva A, Toffanin S, Llovet JM. Linking molecular classification of hepatocellular carcinoma and personalized medicine: preliminary steps. Curr Opin Oncol. 2008;20:444-453. [PMID: 18525342 DOI: 10.1097/CCO.0b013e328302c9e9] [Cited by in Crossref: 52] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
38 Field KM, Michael M. Part II: Liver function in oncology: towards safer chemotherapy use. Lancet Oncol. 2008;9:1181-1190. [PMID: 19038765 DOI: 10.1016/s1470-2045(08)70307-3] [Cited by in Crossref: 47] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]